683 Capital Management »

Kalaris Therapeutics shares owned by 683 Capital Management

Quarter-by-quarter ownership of Kalaris Therapeutics (KLRS) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Kalaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kalaris Therapeutics held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kalaris Therapeutics by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $680k 81k 8.44

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. Put Option (LLY)
Capital One Financial (COF)
Tesla Motors Put Option (TSLA)
NVIDIA Corporation Put Option (NVDA)
Wave Life Sciences SHS (WVE)
Carvana Cl A (CVNA)
Madrigal Pharmaceuticals Put Option (MDGL)
Alnylam Pharmaceuticals (ALNY)
Praxis Precision Medicines I Com New Put Option (PRAX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Protagonist Therapeutics (PTGX)
Gxo Logistics Incorporated Common Stock (GXO)
Hilton Grand Vacations (HGV)
Anaptysbio Inc Common (ANAB)

View all positions for 683 Capital Management

Top funds holding Kalaris Therapeutics

Samsara BioCapital
Rtw Investments
Paradigm Biocapital Advisors
Siren
Alyeska Investment Group
Ikarian Capital
Vanguard Group
ADAR1 Capital Management
Woodline Partners
Boothbay Fund Management
Raymond James Financial
Renaissance Technologies
Redmile Group
Geode Capital Management
683 Capital Management

View all funds holding Kalaris Therapeutics